 The Phosphate Company Ltd Q2FY26 loss at Rs. 2.48 crore
The Phosphate Company Ltd Q2FY26 loss at Rs. 2.48 crore Emami Paper Mills Ltd Q2 FY2026 profit at Rs. 6.58 crores
Emami Paper Mills Ltd Q2 FY2026 profit at Rs. 6.58 crores Maruti Suzuki India Ltd Q2 FY2026 consolidated PAT slips QoQ to Rs. 3349 crores
Maruti Suzuki India Ltd Q2 FY2026 consolidated PAT slips QoQ to Rs. 3349 crores RattanIndia Power Ltd consolidated Q2FY26 loss at Rs. 31.55 crores
RattanIndia Power Ltd consolidated Q2FY26 loss at Rs. 31.55 crores Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26
Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26 
              Surya Pharmaceutical Ltd had earlier announced that the Board of Directors of the Company at its meeting held on October 28, 2006, inter alia, has revised the convertibility of Foreign Currency Convertible Bonds issued by the Company, in terms of Reset Clause 7.2.4 of the Trust Deed Agreement, whereby effective October 28, 2006 onwards, the Company shall allot 313.1324 fully paid Equity shares for each FCCB of USD 1000.00. The Authorised Capital of the Company is sufficient to accommodate the marginal increase in Equity Shares to be issued upon conversion.
The Company has now announced that the number of shares to be allotted upon conversion was erroneously reported as "313.1324" instead on "315.9011".
Hence the correct number of shares to be allotted upon conversion is "315.9011".